University spinout receives £1.2million government funding to tackle antimicrobial resistance

�鶹��ý

University spinout receives £1.2million government funding to tackle antimicrobial resistance

Amprologix was established in 2018 and has been awarded funding by the Small Business Research Initiative, part of Innovate UK

Mr Alan Williams

Media and Communications Manager

Corporate Communications (Marketing and Communications)

4 February 2019

Amprologix Limited, a �鶹��ý spinout company, has won a £1.2 million contract from the Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.

Amprologix was established in 2018 to commercialise the work of Mathew Upton, Professor of Medical Microbiology in the University’s Institute of Translational and Stratified Medicine (ITSMed).

The company has now been awarded funding by the (SBRI), part of Innovate UK, to make its epidermicin NI01 antibiotic ready for the first phase of human clinical trials during early 2021. Amprologix’s first product is expected to be a nasal cream containing epidermicin NI01 to prevent MRSA infections.

Epidermicin is derived from bacteria found on human skin, and work conducted to date shows a single dose to be as effective as six doses of the current gold standard treatment in a relevant model of MRSA infection.

Antimicrobial-resistant bacteria kill more than 25,000 people a year in Europe. The drug-resistant ‘superbug’ MRSA was named last year as a “high priority” target for antibiotic research by the World Health Organisation and it is a leading cause of healthcare associated infection (HCAI).

Professor Upton initially developed the patented technology while at the University of Manchester, which owns an equity share in the company through UMI3 Ltd, its commercialisation arm. , the University’s commercialisation partner, holds a 10% stake in return for providing a range of commercialisation services.

Professor Upton, chief scientific officer at Amprologix, said:

“I feel very strongly that epidermicin has excellent potential for use in nasal decolonisation to prevent skin and wound infections, like those caused by MRSA. Development of NI01 could have immense benefits for patients, so I’m genuinely excited about this work and generating the data needed to enter phase 1 trials.”

Dr Gordon Barker, chief executive officer of Amprologix, added:

“Despite the urgent need for new antibiotics and new approaches to treatment, it remains extremely difficult to fund new drug discovery ventures in this space. The government-backed SBRI programme is a world-leading scheme to address this market failure and we’re really grateful for their support, which will accelerate the development of next generation life-saving medicines like NI01.”

Amprologix has already secured industry involvement in its work through a strategic partnership with Ingenza Limited. Ingenza, a leader in industrial biotechnology and synthetic biology, is also a shareholder in Amprologix and has been developing a bespoke recombinant process for production of epidermicin.

For the SBRI-funded project, Professor Upton will optimise the formulation of epidermicin and conduct a pre-clinical toxicology evaluation. Amprologix will license optimised microbial based production technology from Ingenza’s biologics manufacturing platform to produce the new antibiotics at scale.

Professor Upton is also working separately with Ingenza, IBM and the National Physical Laboratory, using Artificial Intelligence to create a portfolio of novel, adaptable antibiotic candidates for future exploitation.

Dr Ian Fotheringham, managing director of Ingenza, said:

“We are developing advanced biologics manufacturing technologies to address exactly this kind of critical unmet therapeutic need. Our platform will underpin the future success of this exciting new family of potent and selective antimicrobials.”

Neil Crabb, chief executive officer of Frontier IP, said:

“We’re delighted the SBRI is backing this programme, which validates the best approach to IP commercialisation. Through Amprologix and Professor Upton’s ground-breaking science, there is huge potential to prove the efficacy of epidermicin and identify further new antibiotics that can be manufactured at scale.”

Find out more about the �鶹��ý's spinout companies

Fieldwork Robotics secures funding to accelerate development of harvesting robots 19 March 2021
Robotics spinout wins Innovate UK grant to support work through pandemic 17 November 2020
Spinout secures government funding to advance power technology 11 August 2020
Spinout signs agreement with Bosch to further development of harvesting robots 6 July 2020
Scientists make step forward in development of COVID-19 animal vaccines 23 June 2020
Spinout raises funding to accelerate tests for harmful bacteria 4 May 2020

More related news

Fieldwork Robotics has been awarded £145,000 to accelerate the development of its robotics technology

�鶹��ý Institute of Health and Care Research

From basic research discovering the causes of disease, through to evaluating novel ways of delivering care to the most vulnerable people in society, our thriving community conducts adventurous world-leading research

Transformation in life course, ageing, methodologies, eHealth, technology and interventions in health, social care, lifestyle and wellbeing.

Find out more about �鶹��ý Institute of Health and Care Research